MTM – News & events

News & events

Latest news

Get the latest updates and news from MTM

November 8, 2024

MTM announces Lucia Bio, the first company in the newly established Brisbane pod in collaboration with UniQuest

Developing brain penetrant Syk inhibitors for neurodegenerative conditions

November 21, 2024

MTM Achieves Prestigious Great Place to Work Certification

Employees Cite Genuine, People-First Culture

November 6, 2024

Groundbreaking New Immuno-Oncology Platform to Leverage MTM Bioinformatics

MTM’s work directly contributes to the development of personalized, more effective therapies.

Melio Bio - the first company in the MTM London Pod

Melio Bio, co-created by MTM is focused on the discovery and development of GPCR inhibitors for cardiometabolic disease

MTM named one of the UK’s Best Workplaces™ 2024

We are incredibly proud that we have been named in the top 25 UK’s Best Workplaces™ 2024 List by Great Place To Work®

September 27, 2023

Pathios Awarded Innovate UK Grant to Evaluate Preclinical Brain Tumor Models

Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer

September 13, 2023

ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant

ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant

Promising Preclinical Data from Research Collaboration with Immunocore

Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American A

ThirtyFiveBio data debut: AACR 2023 poster presentation

ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference.

Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769

Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours

ThirtyFiveBio Stealth Emergence – presentation of first data at AACR23

ThirtyFiveBio emerges from stealth with presentation of first data from GPR35 Antagonist Program at AACR 2023.

January 26, 2023

$49 Million Series B Financing to Advance Neoantigen Creation Approaches

Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches

November 16, 2022

Clinical Supply Agreement for new trail with Regeneron and Libtayo®

Grey Wolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo®

Upcoming events

Come and meet us, and have a chat to learn more

Wed

30

Oct 2024

AusBiotech 2024

Melbourne, Australia

The MTM team are attending AusBiotech, keen to understand more about the Australian biotech landscape as we prepare to take our unique model global.

Wed

6

Nov 2024

BIO Europe

Stockholm, Sweden

The MTM team will be attending BIO Eurpope, connecting with partners across the global life science ecosystem to propel dealmaking and innovation.

Transforming lives through collaborative innovation